494 related articles for article (PubMed ID: 17360380)
21. Transgenic expression of human CD47 reduces phagocytosis of porcine endothelial cells and podocytes by baboon and human macrophages.
Nomura S; Ariyoshi Y; Watanabe H; Pomposelli T; Takeuchi K; Garcia G; Tasaki M; Ayares D; Sykes M; Sachs D; Johnson R; Yamada K
Xenotransplantation; 2020 Jan; 27(1):e12549. PubMed ID: 31495971
[TBL] [Abstract][Full Text] [Related]
22. Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.
Theocharides AP; Jin L; Cheng PY; Prasolava TK; Malko AV; Ho JM; Poeppl AG; van Rooijen N; Minden MD; Danska JS; Dick JE; Wang JC
J Exp Med; 2012 Sep; 209(10):1883-99. PubMed ID: 22945919
[TBL] [Abstract][Full Text] [Related]
23. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis.
Oldenborg PA; Gresham HD; Lindberg FP
J Exp Med; 2001 Apr; 193(7):855-62. PubMed ID: 11283158
[TBL] [Abstract][Full Text] [Related]
24. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.
Matozaki T; Murata Y; Okazawa H; Ohnishi H
Trends Cell Biol; 2009 Feb; 19(2):72-80. PubMed ID: 19144521
[TBL] [Abstract][Full Text] [Related]
25. Autoimmune animal models in the analysis of the CD47-SIRPα signaling pathway.
Murata Y; Saito Y; Kaneko T; Kotani T; Kaneko Y; Ohnishi H; Matozaki T
Methods; 2014 Jan; 65(2):254-9. PubMed ID: 24091004
[TBL] [Abstract][Full Text] [Related]
26. Innate immune 'self' recognition: a role for CD47-SIRPalpha interactions in hematopoietic stem cell transplantation.
van den Berg TK; van der Schoot CE
Trends Immunol; 2008 May; 29(5):203-6. PubMed ID: 18394962
[TBL] [Abstract][Full Text] [Related]
27. CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.
Gao L; Chen K; Gao Q; Wang X; Sun J; Yang YG
Oncotarget; 2017 Apr; 8(14):22406-22413. PubMed ID: 27283989
[TBL] [Abstract][Full Text] [Related]
28. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
Front Immunol; 2020; 11():18. PubMed ID: 32082311
[TBL] [Abstract][Full Text] [Related]
29. The suppression of inflammatory macrophage-mediated cytotoxicity and proinflammatory cytokine production by transgenic expression of HLA-E.
Maeda A; Kawamura T; Ueno T; Usui N; Eguchi H; Miyagawa S
Transpl Immunol; 2013 Dec; 29(1-4):76-81. PubMed ID: 23994719
[TBL] [Abstract][Full Text] [Related]
30. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
31. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
32. The CD47 pathway is deregulated in human immune thrombocytopenia.
Catani L; Sollazzo D; Ricci F; Polverelli N; Palandri F; Baccarani M; Vianelli N; Lemoli RM
Exp Hematol; 2011 Apr; 39(4):486-94. PubMed ID: 21211546
[TBL] [Abstract][Full Text] [Related]
33. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
34. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
35. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
36. [Role of CD47 in hematologic malignancies].
Su GH; Zhao YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1631-4. PubMed ID: 24370062
[TBL] [Abstract][Full Text] [Related]
37. The 'metabolon,' CD47, and the 'phagocytic synapse': molecular co-localization and species divergence.
Subramanian S; Tsai R; Discher DE
Transfus Clin Biol; 2006; 13(1-2):31-8. PubMed ID: 16581280
[TBL] [Abstract][Full Text] [Related]
38. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
[TBL] [Abstract][Full Text] [Related]
39. Cd47-Sirpα interaction and IL-10 constrain inflammation-induced macrophage phagocytosis of healthy self-cells.
Bian Z; Shi L; Guo YL; Lv Z; Tang C; Niu S; Tremblay A; Venkataramani M; Culpepper C; Li L; Zhou Z; Mansour A; Zhang Y; Gewirtz A; Kidder K; Zen K; Liu Y
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5434-43. PubMed ID: 27578867
[TBL] [Abstract][Full Text] [Related]
40. A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer.
Huang Y; Lv SQ; Liu PY; Ye ZL; Yang H; Li LF; Zhu HL; Wang Y; Cui LZ; Jiang DQ; Hao FY; Xu HM; Jin HJ; Qian QJ
Mol Oncol; 2020 Mar; 14(3):657-668. PubMed ID: 31899582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
